Singular Genomics Systems (NASDAQ:OMIC) Trading Up 0.9% – Should You Buy?

Singular Genomics Systems, Inc. (NASDAQ:OMIC) was up 0.9% on Monday . The company traded as high as $19.90 and last traded at $19.80. Approximately 4,148 shares changed hands during trading, a decline of 75% from the average daily volume of 16,293 shares. The stock had previously closed at $19.62.

Singular Genomics Systems Trading Up 0.9 %

The firm has a market capitalization of $49.74 million, a P/E ratio of -0.56 and a beta of 1.82. The company has a quick ratio of 6.67, a current ratio of 7.37 and a debt-to-equity ratio of 0.04. The business’s 50 day moving average is $20.76 and its two-hundred day moving average is $14.07.

Singular Genomics Systems (NASDAQ:OMIC) last announced its earnings results on Tuesday, November 12th. The company reported ($6.72) EPS for the quarter, topping the consensus estimate of ($8.05) by $1.33. Singular Genomics Systems had a negative return on equity of 57.87% and a negative net margin of 3,237.89%. The firm had revenue of $0.41 million for the quarter, compared to analysts’ expectations of $0.74 million.

Hedge Funds Weigh In On Singular Genomics Systems

A hedge fund recently raised its stake in Singular Genomics Systems stock. Geode Capital Management LLC grew its position in Singular Genomics Systems, Inc. (NASDAQ:OMIC) by 7.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,962 shares of the company’s stock after buying an additional 1,193 shares during the quarter. Geode Capital Management LLC owned approximately 0.72% of Singular Genomics Systems worth $282,000 at the end of the most recent quarter. 65.80% of the stock is currently owned by institutional investors and hedge funds.

Singular Genomics Systems Company Profile

Singular Genomics Systems, Inc, a life science technology company, develops next generation sequencing and multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables for applications comprising single cell gene expression and proteomics, in situ RNA sequencing, and spatial RNA and proteomics applications for tissue.